<?xml version="1.0" encoding="UTF-8"?>
<p id="Par50">Prevention of the cytokine storm may be one of the solution to save the patients with severe COVID-19 pneumonia. Limited pre-clinical data suggested that systemic mesenchymal stem cells (MSCs) administration could cure or significantly improved the functional outcomes in seven SARS-CoV2 patients without any adverse effect [
 <xref ref-type="bibr" rid="CR92">92</xref>]. Addition of anticytokinic biological agents, like anti-IL-1 (anakinra) [
 <xref ref-type="bibr" rid="CR93">93</xref>] or anti-IL-6 (tocilizumab (TCZ)) [
 <xref ref-type="bibr" rid="CR94">94</xref>] are also recommended.
</p>
